Cyrille Hulin

Summary

Affiliation: CHU de Nancy
Country: France

Publications

  1. ncbi Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial
    Cyrille Hulin
    Service d Hematologie, rue du Morvan, Centre Hospitalier Universitaire de Nancy Brabois, 54511 Vandoeuvre, France
    J Clin Oncol 27:3664-70. 2009
  2. ncbi [New treatment of multiple myeloma]
    C Hulin
    Service d hématologie et de médecine interne, CHU de Nancy, Hopitaux de Brabois, rue du Morvan, 54511 Vandoeuvre, France
    Rev Med Interne 28:682-8. 2007
  3. ncbi Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
    Thierry Facon
    Service d Hematologie, Centre Hospitalier Universitaire, Lille, France
    Lancet 370:1209-18. 2007
  4. ncbi Maintenance therapy with thalidomide improves survival in patients with multiple myeloma
    Michel Attal
    Service d Hematologie, Hopital Purpan, Place du Dr Baylac, 31059 Toulouse, France
    Blood 108:3289-94. 2006
  5. ncbi Hematologic recovery after autologous PBPC transplantation: importance of the number of postthaw CD34+ cells
    Pierre Feugier
    Department of Hematology, University Hospital, Nancy, France
    Transfusion 43:878-84. 2003
  6. ncbi Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
    Jesus F San Miguel
    Hospital Universitario Salamanca, CIC, IBMCC USAL CSIC, Salamanca, Spain
    N Engl J Med 359:906-17. 2008
  7. ncbi Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy
    Pieter Sonneveld
    Department of Hematology, Erasmus Medical Center, Rotterdam, Netherlands
    Cancer 112:1529-37. 2008
  8. ncbi Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials
    P Moreau
    Hematology Department, University Hospital, Nantes, France
    Leukemia 21:2020-4. 2007
  9. ncbi [Granulocyte sarcoma of the pancreas without extra-pancreatic location]
    S Dimicoli
    , CHU Nancy-Brabois, , 54511 Vandoeuvre
    Presse Med 31:1024-6. 2002

Collaborators

Detail Information

Publications10

  1. ncbi Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial
    Cyrille Hulin
    Service d Hematologie, rue du Morvan, Centre Hospitalier Universitaire de Nancy Brabois, 54511 Vandoeuvre, France
    J Clin Oncol 27:3664-70. 2009
    ..This randomized, placebo-controlled, phase III trial investigated the efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed myeloma...
  2. ncbi [New treatment of multiple myeloma]
    C Hulin
    Service d hématologie et de médecine interne, CHU de Nancy, Hopitaux de Brabois, rue du Morvan, 54511 Vandoeuvre, France
    Rev Med Interne 28:682-8. 2007
    ..They have an impact on the multiple myeloma treatment strategies and on the disease course itself...
  3. ncbi Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
    Thierry Facon
    Service d Hematologie, Centre Hospitalier Universitaire, Lille, France
    Lancet 370:1209-18. 2007
    ..We assessed whether the addition of thalidomide to this combination, or reduced-intensity stem cell transplantation, would improve survival...
  4. ncbi Maintenance therapy with thalidomide improves survival in patients with multiple myeloma
    Michel Attal
    Service d Hematologie, Hopital Purpan, Place du Dr Baylac, 31059 Toulouse, France
    Blood 108:3289-94. 2006
    ..4). Thalidomide is an effective maintenance therapy in patients with multiple myeloma. Maintenance treatment with pamidronate does not decrease the incidence of bone events...
  5. ncbi Hematologic recovery after autologous PBPC transplantation: importance of the number of postthaw CD34+ cells
    Pierre Feugier
    Department of Hematology, University Hospital, Nancy, France
    Transfusion 43:878-84. 2003
    ..It is not clear whether the quantification of CFU-GM and CD34+ cells should be done on fresh components and after cryopreservation, which better represents the actual composition of the graft...
  6. ncbi Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
    Jesus F San Miguel
    Hospital Universitario Salamanca, CIC, IBMCC USAL CSIC, Salamanca, Spain
    N Engl J Med 359:906-17. 2008
    ..This phase 3 study compared the use of melphalan and prednisone with or without bortezomib in previously untreated patients with multiple myeloma who were ineligible for high-dose therapy...
  7. ncbi Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy
    Pieter Sonneveld
    Department of Hematology, Erasmus Medical Center, Rotterdam, Netherlands
    Cancer 112:1529-37. 2008
    ....
  8. ncbi Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials
    P Moreau
    Hematology Department, University Hospital, Nantes, France
    Leukemia 21:2020-4. 2007
    ..The achievement of either complete response or very good partial response after HDT was also a powerful independent prognostic factor for both OS and EFS...
  9. ncbi [Granulocyte sarcoma of the pancreas without extra-pancreatic location]
    S Dimicoli
    , CHU Nancy-Brabois, , 54511 Vandoeuvre
    Presse Med 31:1024-6. 2002
    ..Immuno-histochemical methods are essential in order to obtain correct diagnosis. Despite the localized nature of the tumor, intensive AML-type chemotherapy is necessary...